TY - JOUR
T1 - Diagnosis and treatment of adrenal insufficiency including adrenal crisis
T2 - A japan endocrine society clinical practice guideline
AU - Yanase, Toshihiko
AU - Tajima, Toshihiro
AU - Katabami, Takuyuki
AU - Iwasaki, Yasumasa
AU - Tanahashi, Yusuke
AU - Sugawara, Akira
AU - Hasegawa, Tomonobu
AU - Mune, Tomoatsu
AU - Oki, Yutaka
AU - Nakagawa, Yuichi
AU - Miyamura, Nobuhiro
AU - Shimizu, Chikara
AU - Otsuki, Michio
AU - Nomura, Masatoshi
AU - Akehi, Yuko
AU - Tanabe, Makito
AU - Kasayama, Soji
N1 - Publisher Copyright:
© The Japan Endocrine Society.
PY - 2016
Y1 - 2016
N2 - This clinical practice guideline of the diagnosis and treatment of adrenal insufficiency (AI) including adrenal crisis was produced on behalf of the Japan Endocrine Society. This evidence-based guideline was developed by a committee including all authors, and was reviewed by a subcommittee of the Japan Endocrine Society. The Japanese version has already been published, and the essential points have been summarized in this English language version. We recommend diagnostic tests, including measurement of basal cortisol and ACTH levels in combination with a rapid ACTH (250 μg corticotropin) test, the CRH test, and for particular situations the insulin tolerance test. Cut-off values in basal and peak cortisol levels after the rapid ACTH or CRH tests are proposed based on the assumption that a peak cortisol level ≥18 μg/ dL in the insulin tolerance test indicates normal adrenal function. In adult AI patients, 15-25 mg hydrocortisone (HC) in 2-3 daily doses, depending on adrenal reserve and body weight, is a basic replacement regime for AI. In special situations such as sickness, operations, pregnancy and drug interactions, cautious HC dosing or the correct choice of glucocorticoids is necessary. From long-term treatment, optimal diurnal rhythm and concentration of serum cortisol are important for the prevention of cardiovascular disease and osteoporosis. In maintenance therapy during the growth period of patients with 21-hydroxylase deficiency, proper doses of HC should be used, and long-acting glucocorticoids should not be used. Education and carrying an emergency card are essential for the prevention and rapid treatment of adrenal crisis.
AB - This clinical practice guideline of the diagnosis and treatment of adrenal insufficiency (AI) including adrenal crisis was produced on behalf of the Japan Endocrine Society. This evidence-based guideline was developed by a committee including all authors, and was reviewed by a subcommittee of the Japan Endocrine Society. The Japanese version has already been published, and the essential points have been summarized in this English language version. We recommend diagnostic tests, including measurement of basal cortisol and ACTH levels in combination with a rapid ACTH (250 μg corticotropin) test, the CRH test, and for particular situations the insulin tolerance test. Cut-off values in basal and peak cortisol levels after the rapid ACTH or CRH tests are proposed based on the assumption that a peak cortisol level ≥18 μg/ dL in the insulin tolerance test indicates normal adrenal function. In adult AI patients, 15-25 mg hydrocortisone (HC) in 2-3 daily doses, depending on adrenal reserve and body weight, is a basic replacement regime for AI. In special situations such as sickness, operations, pregnancy and drug interactions, cautious HC dosing or the correct choice of glucocorticoids is necessary. From long-term treatment, optimal diurnal rhythm and concentration of serum cortisol are important for the prevention of cardiovascular disease and osteoporosis. In maintenance therapy during the growth period of patients with 21-hydroxylase deficiency, proper doses of HC should be used, and long-acting glucocorticoids should not be used. Education and carrying an emergency card are essential for the prevention and rapid treatment of adrenal crisis.
KW - Adrenal crisis
KW - Adrenal insufficiency
KW - Congenital adrenal hyperplasia
KW - Cortisol
KW - Hydrocortisone
UR - http://www.scopus.com/inward/record.url?scp=84989172113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989172113&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ16-0242
DO - 10.1507/endocrj.EJ16-0242
M3 - Article
C2 - 27350721
AN - SCOPUS:84989172113
SN - 0918-8959
VL - 63
SP - 765
EP - 784
JO - Endocrine Journal
JF - Endocrine Journal
IS - 9
ER -